Hello,

Welcome to our flagship newsletter, MarketBeat Daily Ratings.

We'll deliver the latest "Buy" and "Sell" ratings from Wall Street's top-rated analysts directly to your inbox each morning.

But first, we need you to do two quick things:

1. Hit reply, and send a simple "Yes." Just one word. This tells Google (and other emails providers) that you actually want to get our newsletter.

2. After that, this link to confirm your subscription. That will tell us that you received our welcome email and that we should start sending your daily report. 

Confirm your subscription here.

After you have completed these two steps, we would like to gift you a free copy of one of our most popular investing reports: 7 Stocks to Buy and Hold Forever. You can download the report with this link.

Thank you again for subscribing. We look forward to being an important part of your investing journey

Matthew Paulson
Founder and CEO, MarketBeat.

P.S. If you didn’t intend to subscribe, no problem—you can unsubscribe with this link.

(ARReply-161)

Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?

Submitted by Chris Markoch. Article Posted: 9/2/2026.

For a few days in mid-August, Wendy's (NASDAQ: WEN) traded like a company on the verge of being taken private. Reports surfaced on Aug. 12 that Trian Fund Management, Nelson Peltz's activist firm and a roughly 16% shareholder in Wendy's, was assembling a consortium to explore a buyout.

The stock ripped nearly 15% higher. That briefly pushed shares toward the $9 mark, putting WEN in positive territory for 2026.

Moderna Doubled in One Day. This Medical Stock Could Be Next (Ad)

Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.

It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.

Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States.

Click here to learn about this new era of medical technology

The move didn't last. Reuters reported that Trian had no current plans to bid, and the stock gave back the entire rally in a single session, sliding back toward the high-$7 range. Trian's stated reasoning, including concerns about performance, valuation and strategic direction, read less like a passing decision and more like a well-capitalized insider declining to catch a falling knife.

That reversal came at a time when Wendy's was already struggling. In its Q2 2026 earnings report, delivered on Aug. 7, Wendy's reported a 7% drop in U.S. same-restaurant sales, a 41% decline in net income and a withdrawn full-year 2026 outlook. CEO Bob Wright didn't sugarcoat the results, telling investors that performance was "not at our potential."

But that's not quite where the story ends. In the weeks since, WEN has quietly clawed back most of that decline. That recovery is why investors should take the rally seriously, rather than dismissing it as mere rhetoric.

Why WEN Started Trading Like a Meme Stock

Five years ago, Wendy's was trading at an all-time high of around $25. Since then, WEN has been in a steep decline, bringing the stock to around $6.22 per share in June 2026. That put it perilously close to penny-stock territory.

The decline hasn't been without merit. The quick-service restaurant industry has struggled to find the right mix of price and value for an increasingly stretched core consumer. Wendy's hasn't helped matters with execution errors.

So why did WEN soar 15% in such a brief period? It wasn't all about Trian. More than 32% of its float was sold short. Savvy traders saw an opportunity to force some of those short sellers to cover their positions. The move may not technically qualify as a short squeeze, but that term helps explain why the stock moved so sharply.

This is an important distinction for investors. A stock with substantial short interest can move dramatically on relatively little new information. When sentiment is already heavily skewed to the bearish side, even a temporary positive catalyst can force traders to reassess their positions.

That doesn't necessarily mean the underlying business has improved.

It does, however, mean that WEN can remain unusually volatile as investors debate whether the worst of the company's decline has already been priced into the stock.

Wendy's Stock Technical Analysis Shows a Bullish Setup, But Not a Confirmed Turnaround

However, just as it did in early July, investors considering a position in WEN should watch the chart. The stock appears to be finding support at an ascending 50-day simple moving average, which could mark the start of a bullish move.

The technical picture is particularly interesting because WEN has recovered from the initial Trian-related reversal rather than simply falling back to its June lows.

That creates a potential test for the bulls. If shares can continue holding above the 50-day moving average and establish higher lows, traders will have a technical argument that the longer-term downtrend may be losing some of its force. Conversely, a decisive break below that moving average would weaken the bullish setup and suggest that the recent recovery was another temporary bounce.

The MACD may be the deciding factor. In recent months, momentum has clearly been on the bulls' side. The coming weeks will determine whether that momentum was due to the Trian news or whether investors see a genuine opportunity.

For technical traders, the distinction matters. Momentum that survives the removal of a major catalyst is generally more meaningful than momentum that disappears as soon as the catalyst does.

Why Betting Against WEN May Be the Wrong Bet

Wendy's is giving investors a genuinely mixed picture. At around 12 times earnings, WEN is overvalued by some measures.

Many investors won't get excited about the stock until the company starts showing positive year-over-year earnings.

That said, Wendy's has been clearing a low bar for earnings over the past several quarters.

Institutions have also been buying the stock. That wouldn't happen if they believed the company's outlook was hopeless. Instead, their purchases appear to reflect a calculation that the sell-off has been overdone.

That buying activity is directly contradicted by analyst sentiment, which leans bearish with a consensus Reduce rating. Furthermore, of the 21 analysts that MarketBeat tracks, six have a Sell rating on WEN.

So, Was the Rally Ever Real?

The honest answer is yes—partly. The initial 15% pop was driven mostly by enthusiasm for the deal and short covering. That part of the move was always likely to unwind once Trian stepped back.

The subsequent recovery to the mid-$8 range looks different. It appears more like value buyers and technical traders stepping in at a level where the stock had already priced in a great deal of bad news.

The catch is that, without Trian as a backstop, there's no buyout floor left under the stock. Whatever happens from here rests entirely on Wright's turnaround plan actually working. The chart says momentum currently favors the bulls. The fundamentals say that momentum still has something to prove.